Recruiting

Observational Study

Sponsor:

Optos, PLC

Code:

NCT07149740

Conditions

Retinal Disease

Healthy

Glaucoma

Corneal Diseases

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Accepted

Interventions

OCT

Study Details

Brief summary:

The objective of this study is to gather Optical Coherence Tomography (OCT) data on normal and diseased eyes

Conditions

Retinal Disease

Healthy

Glaucoma

Corneal Diseases

Study ID

NCT07149740

Start date

Jun 26, 2025

Status verified date

Feb, 2026

Completion date

May 1, 2026

Anticipated

Primary completion date

May 1, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 22+

Healthy Volunteers: Accepted

Inclusion/Exclusion Criteria Inclusion Criteria for Retinal Disease Group

1. Participants 22 years of age or older on the date of informed consent
2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
3. BCVA 20/400 or better in the study eye
4. Participants presenting at the site with retinal disease
5. Diagnosis of some type of retinal pathology by investigator, may include, but not limited to: Macular Degeneration (including participants with drusen and geographic atrophy and choroidal neovascularization), Diabetic Macular Edema, Diabetic Retinopathy, Macular Hole, Epiretinal Membrane, Central Serous Retinopathy and others

Exclusion Criteria for Retinal Disease Group

1. Participants unable to tolerate ophthalmic imaging
2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
4. Presence of glaucoma or any ocular pathology other than a retinal pathology in the study eye as determined by self-report and/or investigator assessment at the study visit;

Inclusion Criteria for Glaucoma Group

1. Participants 22 years of age or older on the date of informed consent
2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
3. BCVA 20/40 or better in the study eye
4. History of Visual field defects within the previous year from the study visit or measured the day of the study visit consistent with glaucomatous optic nerve damage with at least one of the following two findings:

1. On pattern deviation (PD), there exists a cluster of 3 or more points in an expected location of the visual field depressed below the 5% level, at least 1 of which is depressed below the 1% level;
2. Glaucoma hemi-field test "outside normal limits."
5. Glaucomatous optic nerve damage as evidenced by any of the following optic disc or retinal nerve fiber layer structural abnormalities:

1. Diffuse thinning, focal narrowing, or notching of the neuroretinal rim, especially at the inferior or superior poles with or without disc hemorrhage;
2. Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue

Exclusion Criteria for Glaucoma Group

1. Participants unable to tolerate ophthalmic imaging
2. Participants not able to obtain acceptable OCT images due to ocular media opacity or other reasons
3. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
4. No reliable visual field test result within the previous year from the study visit, defined as fixation losses > 33% or false positives > 33%, or false negatives > 33% in the study eye
5. Presence of any ocular pathology except glaucoma in the study eye Inclusion Criteria for Corneal Group

1\. Participants 22 years of age or older on the date of informed consent 2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent 3. Participants presenting at the site with corneal disease, for example but not limited to, corneal disorders due to contact lens wear, post-refractive surgery, dry eye, keratoconus 4. Participant is able to comply with the study procedures.

Exclusion Criteria for Corneal Group

1. Participants unable to tolerate ophthalmic imaging
2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images.

Inclusion Criteria for Normal Group

1. Participants 22 years of age or older on the date of informed consent
2. Participants able to understand the written informed consent and willing to participate as evidenced by signing the informed consent
3. Participants presenting at the site with normal eyes (Cataracts, LASIK, PRK, and peripheral pathology that does not affect the posterior pole region, for example lattice and peripheral drusen, are allowed).
4. BCVA 20/40 or better (each eye)
5. Participant is able to comply with the study procedures

Exclusion Criteria for Normal Group

1. Participants unable to tolerate ophthalmic imaging
2. Participant has a condition or is in a situation which the investigator feels may put the participant at significant risk, may confound the study results, or may interfere significantly with the participant's participation in the study
3. Participant with ocular media not sufficiently clear to obtain acceptable OCT images
4. History of leukemia, dementia or multiple sclerosis

Study Design

Enrollment

180 participants

Anticipated

Interventions and Outcome Measures

Arms

Retinal Disease

Healthy

Glaucoma

Corneal Disease

Interventions

OCT

A10900 is an optical coherence tomography device

Primary outcome measure

  • Number of OCT Scans [ Time Frame: 1 year ]

Central Contacts and Locations

Locations

Ketchum Health

Recruiting

Anaheim, California, United States, 92807

Contacts

Eye Disease Consultants, LLC

Recruiting

West Hartford, Connecticut, United States, 06107

Contacts

Charles Retina Institute

Recruiting

Germantown, Tennessee, United States, 38138

Contacts

More Information

Sponsor

Optos, PLC

Last update posted

Feb 13, 2026

Last verified

Feb, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Optos, PLC on 2026-02-13.